Nonetheless, given the current research focus, using established immune checkpoint inhibitors, such as PD-L1, combined with new immune targets like CD47, along with various immunotherapy regimens—including bispecific antibodies or monoclonal antibodies combined with immunotherapy—represents the most promising approach for achieving precision therapy in gastrointestinal tumors currently. Here, CD47 is linked to digestive system neoplasm.